4
Clinical Trials associated with Compound Huangdai Tablet / Unknown statusPhase 3IIT Implement Randomized, Controlled, International Multi-center Clinical Trial of Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Non-high-risk Acute Promyelocytic Leukaemia
Acute Promyelocytic Leukaemia (APL) has been known as a type of cancer, which is of great significance to improve its eradication rate. Recent clinical trials show that ATRA plus ATO treatment regimen can result in complete response (CR) in 90-94% of patients and 5-year disease-free survival (DFS) in more than 90% of patients. However, the ATRA plus ATO treatment regimen can achieve considerate survival rate, patients still need to receive infusion therapy in hospital. If oral arsenic can replace intravenous ATO without reduction of the efficacy, patients would not need to be administered to receive treatment, which would highly increase their quality of lives. Phase I, II Clinical trials have verified the security and efficacy of the Compound Realgar-Indigo Naturalis Formula. Compound Realgar-Indigo Naturalis Formula was approved by the China Food and Drug Administration in 2009. Investergators have done a multi-centre, randomized, controlled, non-inferiority phase 3 clinical trial in China. And the result showed that oral arsenic plus retinoic acid has an anti-leukaemic efficacy similar to the intravenous arsenic treatment. So Investigators performed an international multi-center, Randomized controlled clinical trialsto compare the efficacy of oral RIF plus ATRA with intravenous arsenic trioxide plus ATRA in patients with non-high-risk APL in different racial types.
复方黄黛片联合应用维甲酸治疗急性早幼粒细胞白血病的疗效和安全性的开放、多中心的IV期临床研究
[Translation] An open, multicenter phase IV clinical study on the efficacy and safety of Fufang Huangdai tablets combined with retinoic acid in the treatment of acute promyelocytic leukemia
研究复方黄黛片和维甲酸联合应用治疗急性早幼粒细胞白血病的远期疗效和安全性
[Translation] To study the long-term efficacy and safety of the combined use of compound Huangdai tablets and retinoic acid in the treatment of acute promyelocytic leukemia
与单用甲磺酸伊马替尼比较,复方黄黛片联合甲磺酸伊马替尼治疗慢性粒细胞白血病的疗效和安全性III期临床研究
[Translation] Phase III clinical study on the efficacy and safety of Fufang Huangdai tablets combined with imatinib mesylate in the treatment of chronic myeloid leukemia compared with imatinib mesylate alone
与单用甲磺酸伊马替尼比较,复方黄黛片联合甲磺酸伊马替尼治疗慢性期Ph+慢性粒细胞白血病的疗效和安全性。
[Translation] Compared with imatinib mesylate alone, the efficacy and safety of compound Huangdai tablets combined with imatinib mesylate in the treatment of chronic phase Ph+ chronic myeloid leukemia.
100 Clinical Results associated with Compound Huangdai Tablet
100 Translational Medicine associated with Compound Huangdai Tablet
100 Patents (Medical) associated with Compound Huangdai Tablet
100 Deals associated with Compound Huangdai Tablet